← Leaderboards
Marcus Webb
Privo Technologies, Llc
$1,664,854
Attributed
$3,329,707
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2024–25$2.5M$1.9M$1.3M$625K$0
'24
'25
Funding mix
By agency
NIH$3,329,707 · 1
By mechanism
R44$3,329,707 · 1
Top collaborators
- Manijeh N Goldberg2 shared
Most similar at Privo Technologies, Llc
Same institution · by research overlap
- Manijeh N Goldberg$11,254,955
- Donna Keith$4,266,547
- Jesse Hall$523,684
- Kuanju Chen$110,338
- Manijeh Goldberg$2,049,944
Others in their field
Other Rising Stars on “Agreement”
- Lauren Miller · Technical Resources International, Inc.$31,120,905
- Cynthia M Visness · Rho Federal Systems Division, Inc.$14,006,776
- Thomas K Karikari · Wake Forest University Health Sciences$13,438,430
- Amanda Burnaugh · Battelle Centers/Pub Hlth Res & Evaluatn$10,086,715
- Suma Babu · Massachusetts General Hospital$9,819,674
- Sabrina Paganoni · Massachusetts General Hospital$9,819,674
Research focus
AgreementAmerican Cancer SocietyAmerican Joint Committee On CancerAreaBasement MembraneBiopsyBloodBusinessesCancer PatientCarcinomaCarcinoma In SituCessation Of LifeChemotherapeutic AgentChemotherapy And/Or RadiationCirculationCisplatinClassificationClinical DevelopmentClinical ResearchClinical TrialsCombined Modality TherapyCommercializationCosmeticsAftercare
Grant awards (2)
Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer)$1,245,681
R44 · FY2025 · CA
Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer)$2,084,026
R44 · FY2024 · CA